A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Active:	Yes
Cancer Type:	Solid Tumor	NCT ID:	NCT05536141
Trial Phases:	Phase I	Protocol IDs:	ARC-20 (primary) NCI-2023-02610 2024-519142-70-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Arcus Biosciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05536141

Summary

The purpose of this study is to evaluate the safety and tolerability of:

- casdatifan when taken alone in participants with advanced solid tumor malignancies
and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and

- casdatifan monotherapy and casdatifan in combination with cabozantinib or
zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose
expansion stage.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.